EDUCATION

Undergraduate Degree

  • University of California at Berkley , 1987 , Berkley , California

Medical School

  • University of Vermont , 1992 , Burlington , Vermont

Residency

  • Rhode Island Hospital, Brown University , Providence , RI

Fellowship

  • Tufts New England Floating Hospital for Children , Boston , Ma

Fellowship

  • Boston Children's Hospital , Boston , MA

PUBLICATIONS

Publications powered by Harvard Catalyst Profiles

  1. A 1-Year Cross-sectional Inflammatory Bowel Disease Surveillance Colonoscopy Cohort Comparing High-definition White Light Endoscopy and Chromoendoscopy. Inflamm Bowel Dis. 2021 04 15; 27(5):594-602. View abstract
  2. Parasitic omental endometrioma: an unexpected iatrogenic sequalae of morcellation in disseminating de novo benign peritoneal disease. J Obstet Gynaecol. 2021 Jan; 41(1):167-168. View abstract
  3. Perineal integrity can be guarded by polishing our intrapartum skills. Aust N Z J Obstet Gynaecol. 2020 06; 60(3):E6. View abstract
  4. Combination Biologic Therapy in Inflammatory Bowel Disease: Experience From a Tertiary Care Center. Clin Gastroenterol Hepatol. 2021 03; 19(3):616-617. View abstract
  5. Intravenous Bevacizumab Reduces Transfusion Requirements and Endoscopic Interventions in Patients With Gastric Antral Vascular Ectasia and Small Bowel Angioectasia. Gastroenterology. 2020 03; 158(4):1162-1163.e4. View abstract
  6. The Combination of Patient-Reported Clinical Symptoms and an Endoscopic Score Correlates Well with Health-Related Quality of Life in Patients with Ulcerative Colitis. J Clin Med. 2019 Aug 05; 8(8). View abstract
  7. Evaluating the value of intrapartum fetal scalp blood sampling to predict adverse neonatal outcomes: A UK multicentre observational study. Eur J Obstet Gynecol Reprod Biol. 2019 Sep; 240:62-67. View abstract
  8. Vedolizumab Drug Level Correlation With Clinical Remission, Biomarker Normalization, and Mucosal Healing in Inflammatory Bowel Disease. Inflamm Bowel Dis. 2019 02 21; 25(3):580-586. View abstract
  9. Narrow band imaging evaluation of duodenal villi in patients with and without celiac disease: A prospective study. World J Gastrointest Endosc. 2019 Feb 16; 11(2):145-154. View abstract
  10. Mechanisms of Disease: Inflammatory Bowel Diseases. Mayo Clin Proc. 2019 01; 94(1):155-165. View abstract
  11. Outcomes of Treatment for Latent Tuberculosis Infection in Patients With Inflammatory Bowel Disease Receiving Biologic Therapy. Inflamm Bowel Dis. 2018 09 15; 24(10):2272-2277. View abstract
  12. Phenotype and Clinical Course of Inflammatory Bowel Disease With Co-existent Celiac Disease. J Crohns Colitis. 2018 Jul 30; 12(8):973-980. View abstract
  13. Clinical Benefit of Capsule Endoscopy in Crohn's Disease: Impact on Patient Management and Prevalence of Proximal Small Bowel Involvement. Inflamm Bowel Dis. 2018 06 08; 24(7):1582-1588. View abstract
  14. Concurrent Sweet's syndrome and myopericarditis following mesalamine therapy. BMJ Case Rep. 2018 Mar 23; 2018. View abstract
  15. Targeting Specific Immunologic Pathways in Crohn's Disease. Gastroenterol Clin North Am. 2017 09; 46(3):577-588. View abstract
  16. Inflammatory Bowel Disease: Updates on Molecular Targets for Biologics. Gut Liver. 2017 Jul 15; 11(4):455-463. View abstract
  17. Aberrant function of myeloid-derived suppressor cells (MDSCs) in experimental colitis and in inflammatory bowel disease (IBD) immune responses. Autoimmunity. 2017 May; 50(3):170-181. View abstract
  18. P616 Natural history and phenotype of inflammatory bowel disease with co-existent celiac disease. J Crohns Colitis. 2017 Feb 01; 11(suppl_1):S394-S395. View abstract
  19. The Role of the Histone Methyltransferase Enhancer of Zeste Homolog 2 (EZH2) in the Pathobiological Mechanisms Underlying Inflammatory Bowel Disease (IBD). J Biol Chem. 2017 Jan 13; 292(2):706-722. View abstract
  20. O-015 YI Alterations in the FOXP3-EZH2 Pathway Associates with Increased Susceptibility to Colitis in Both Mice and Human. Inflamm Bowel Dis. 2016 Mar; 22 Suppl 1:S5-6. View abstract
  21. A case report of sevelamer-associated recto-sigmoid ulcers. BMC Gastroenterol. 2016 Feb 24; 16:20. View abstract
  22. Krüppel-like factor KLF10 deficiency predisposes to colitis through colonic macrophage dysregulation. Am J Physiol Gastrointest Liver Physiol. 2015 Dec 01; 309(11):G900-9. View abstract
  23. Apolipoprotein A-I inhibits experimental colitis and colitis-propelled carcinogenesis. Oncogene. 2016 05 12; 35(19):2496-505. View abstract
  24. Ipilimumab-induced colitis in patients with metastatic melanoma. Melanoma Res. 2015 Aug; 25(4):321-7. View abstract
  25. New-onset paresthesias in inflammatory bowel disease. Gastroenterology. 2015 May; 148(5):906-7. View abstract
  26. An uncommon cause of abdominal pain and fever in a patient with Crohn's disease. Gastroenterology. 2015 May; 148(5):e12-3. View abstract
  27. A novel role for KLF14 in T regulatory cell differentiation. Cell Mol Gastroenterol Hepatol. 2015 Mar 01; 1(2):188-202.e4. View abstract
  28. Predictors of health-related quality of life and adherence in Crohn's disease and ulcerative colitis: implications for clinical management. Dig Dis Sci. 2015 May; 60(5):1366-74. View abstract
  29. Krüppel-like factor KLF10 regulates transforming growth factor receptor II expression and TGF-ß signaling in CD8+ T lymphocytes. . 2015 Mar 01; 308(5):C362-71. View abstract
  30. Pharmacogenetics of inflammatory bowel disease. Pharmacogenomics. 2014 Dec; 15(16):2049-62. View abstract
  31. Immunology of inflammatory bowel disease and molecular targets for biologics. Gastroenterol Clin North Am. 2014 Sep; 43(3):405-24. View abstract
  32. Lymphocyte homing antagonists in the treatment of inflammatory bowel diseases. Gastroenterol Clin North Am. 2014 Sep; 43(3):581-601. View abstract
  33. Prolonged idiopathic gastric dilatation following revascularization for chronic mesenteric ischemia. Ann Gastroenterol. 2014; 27(3):273-275. View abstract
  34. Cytomegalovirus infection of the ileoanal pouch: clinical characteristics and outcomes. Inflamm Bowel Dis. 2013 Oct; 19(11):2394-9. View abstract
  35. Chronic diarrhea after autologous stem cell transplantation for peripheral T-cell lymphoma. Gastroenterology. 2013 Aug; 145(2):e3-5. View abstract
  36. Hepcidin is a key mediator of anemia of inflammation in Crohn's disease. J Crohns Colitis. 2013 Sep; 7(8):e286-91. View abstract
  37. Treatment of experimental murine colitis with CD40 antisense oligonucleotides delivered in amphoteric liposomes. J Control Release. 2013 Feb 10; 165(3):163-72. View abstract
  38. Colorectal cancer screening and surveillance in Crohn's colitis. J Crohns Colitis. 2012 Sep; 6(8):824-9. View abstract
  39. Predicting outcomes after restorative proctocolectomy for ulcerative colitis. Clin Gastroenterol Hepatol. 2012 May; 10(5):447-9. View abstract
  40. Dysplasia and cancer in inflammatory bowel disease. Expert Rev Gastroenterol Hepatol. 2011 Feb; 5(1):59-66. View abstract
  41. Pulmonary manifestations of inflammatory bowel disease: case presentations and review. J Crohns Colitis. 2010 Oct; 4(4):390-7. View abstract
  42. Combination of innate and adaptive immune alterations increased the likelihood of fibrostenosis in Crohn's disease. Inflamm Bowel Dis. 2010 Aug; 16(8):1279-85. View abstract
  43. A case of orbital myositis preceding the intestinal symptoms of Crohn's disease. J Crohns Colitis. 2010 Sep; 4(3):349-50. View abstract
  44. Report of the ECCO workshop on anti-TNF therapy failures in inflammatory bowel diseases: biological roles and effects of TNF and TNF antagonists. J Crohns Colitis. 2010 Oct; 4(4):367-76. View abstract
  45. CD8+ cells protect mice against reinfection with the intestinal parasite Eimeria falciformis. Microbes Infect. 2010 Mar; 12(3):218-26. View abstract
  46. Diagnostic approach to small bowel involvement in inflammatory bowel disease: view of the endoscopist. Dig Dis. 2009; 27(4):476-81. View abstract
  47. Capsule endoscopy in patients with Crohn's disease: diagnostic yield and safety. Gastrointest Endosc. 2010 Jan; 71(1):121-7. View abstract
  48. Immunosuppression impairs response to pneumococcal polysaccharide vaccination in patients with inflammatory bowel disease. Am J Gastroenterol. 2010 Jan; 105(1):148-54. View abstract
  49. Genome-wide association study identifies eight loci associated with blood pressure. Nat Genet. 2009 Jun; 41(6):666-76. View abstract
  50. Musculoskeletal manifestations of inflammatory bowel disease. Inflamm Bowel Dis. 2009 Dec; 15(12):1915-24. View abstract
  51. Crohn's disease: Adalimumab improves quality of life. Nat Rev Gastroenterol Hepatol. 2009 Apr; 6(4):200-1. View abstract
  52. Comparison of commercially available serologic kits for the detection of celiac disease. J Clin Gastroenterol. 2009 Mar; 43(3):225-32. View abstract
  53. Capsule endoscopy in the evaluation and management of inflammatory bowel disease: a future perspective. Expert Rev Mol Diagn. 2009 Jan; 9(1):31-6. View abstract
  54. Six new loci associated with body mass index highlight a neuronal influence on body weight regulation. Nat Genet. 2009 Jan; 41(1):25-34. View abstract
  55. Why are cytokines targeted for biological therapy in IBD? Inflamm Bowel Dis. 2008 Oct; 14 Suppl 2:S121-2. View abstract
  56. Endoscopic evaluation of patients with inflammatory bowel disease. Inflamm Bowel Dis. 2008 Sep; 14(9):1287-97. View abstract
  57. Proximal small intestinal CD detected by CE. Gastrointest Endosc. 2008 Jul; 68(1):202-3; author reply 203-4. View abstract
  58. Visilizumab induces apoptosis of mucosal T lymphocytes in ulcerative colitis through activation of caspase 3 and 8 dependent pathways. Clin Immunol. 2008 Jun; 127(3):322-9. View abstract
  59. Common variants near MC4R are associated with fat mass, weight and risk of obesity. Nat Genet. 2008 Jun; 40(6):768-75. View abstract
  60. Both preoperative perinuclear antineutrophil cytoplasmic antibody and anti-CBir1 expression in ulcerative colitis patients influence pouchitis development after ileal pouch-anal anastomosis. Clin Gastroenterol Hepatol. 2008 May; 6(5):561-8. View abstract
  61. Thiopurine methyltransferase activity combined with 6-thioguanine metabolite levels predicts clinical response to thiopurines in patients with inflammatory bowel disease. Dig Liver Dis. 2008 Jun; 40(6):425-32. View abstract
  62. LDL-cholesterol concentrations: a genome-wide association study. Lancet. 2008 Feb 09; 371(9611):483-91. View abstract
  63. Minimally invasive closure of pediatric umbilical hernias. J Pediatr Surg. 2008 Jan; 43(1):127-30. View abstract
  64. Family history and serology predict Crohn's disease after ileal pouch-anal anastomosis for ulcerative colitis. Dis Colon Rectum. 2008 Jan; 51(1):100-8. View abstract
  65. Diagnostic yield of capsule endoscopy in ulcerative colitis and inflammatory bowel disease of unclassified type (IBDU). Endoscopy. 2008 Jan; 40(1):30-5. View abstract
  66. Does infliximab influence surgical morbidity of ileal pouch-anal anastomosis in patients with ulcerative colitis? Dis Colon Rectum. 2007 Nov; 50(11):1747-53. View abstract
  67. Characterization of FOXP3+CD4+ regulatory T cells in Crohn's disease. Clin Immunol. 2007 Dec; 125(3):281-90. View abstract
  68. Hepatotoxicity of 6-mercaptopurine (6-MP) and Azathioprine (AZA) in adult IBD patients. Am J Gastroenterol. 2007 Nov; 102(11):2488-94. View abstract
  69. A prospective multivariate analysis of clinical factors associated with pouchitis after ileal pouch-anal anastomosis. Clin Gastroenterol Hepatol. 2007 Aug; 5(8):952-8; quiz 887. View abstract
  70. Predicting a change in diagnosis from ulcerative colitis to Crohn's disease: a nested, case-control study. Clin Gastroenterol Hepatol. 2007 May; 5(5):602-8; quiz 525. View abstract
  71. Esophageal Crohn's disease treated successfully with adalimumab. Inflamm Bowel Dis. 2007 May; 13(5):639-40. View abstract
  72. Anti-flagellin (CBir1) phenotypic and genetic Crohn's disease associations. Inflamm Bowel Dis. 2007 May; 13(5):524-30. View abstract
  73. Phenotype and effector function of CC chemokine receptor 9-expressing lymphocytes in small intestinal Crohn's disease. J Immunol. 2007 Mar 01; 178(5):3293-300. View abstract
  74. Expression and functional characterization of FOXP3+ CD4+ regulatory T cells in ulcerative colitis. Inflamm Bowel Dis. 2007 Feb; 13(2):191-9. View abstract
  75. Antibodies to I2 predict clinical response to fecal diversion in Crohn's disease. Inflamm Bowel Dis. 2006 Dec; 12(12):1122-30. View abstract
  76. NOD2 variants and antibody response to microbial antigens in Crohn's disease patients and their unaffected relatives. Gastroenterology. 2007 Feb; 132(2):576-86. View abstract
  77. Patients with inflammatory bowel disease are at risk for vaccine-preventable illnesses. Am J Gastroenterol. 2006 Aug; 101(8):1834-40. View abstract
  78. Familial expression of anti-Escherichia coli outer membrane porin C in relatives of patients with Crohn's disease. Gastroenterology. 2006 Apr; 130(4):1078-85. View abstract
  79. Adalimumab for the treatment of Crohn's disease. Expert Rev Clin Immunol. 2006 Jan; 2(1):11-5. View abstract
  80. Wireless capsule endoscopy in the evaluation of patients with suspected or known Crohn's disease. Endoscopy. 2005 Oct; 37(10):1018-22. View abstract
  81. Elevated platelet count before ileal pouch-anal anastomosis for ulcerative colitis is associated with the development of chronic pouchitis. Am Surg. 2005 Oct; 71(10):821-6. View abstract
  82. Serologic responses in indeterminate colitis patients before ileal pouch-anal anastomosis may determine those at risk for continuous pouch inflammation. Dis Colon Rectum. 2005 Jun; 48(6):1254-62. View abstract
  83. Antibodies to CBir1 flagellin define a unique response that is associated independently with complicated Crohn's disease. Gastroenterology. 2005 Jun; 128(7):2020-8. View abstract
  84. Dominant role for TL1A/DR3 pathway in IL-12 plus IL-18-induced IFN-gamma production by peripheral blood and mucosal CCR9+ T lymphocytes. J Immunol. 2005 Apr 15; 174(8):4985-90. View abstract
  85. Association of anti-tumor necrosis factor therapy with the development of multiple sclerosis. J Clin Gastroenterol. 2005 Apr; 39(4):303-6. View abstract
  86. Safety and efficacy of adalimumab (D2E7) in Crohn's disease patients with an attenuated response to infliximab. Am J Gastroenterol. 2005 Jan; 100(1):75-9. View abstract
  87. Expression and regulation of the chemokine receptor CXCR3 on lymphocytes from normal and inflammatory bowel disease mucosa. Inflamm Bowel Dis. 2004 Nov; 10(6):778-88. View abstract
  88. Crohn's ileitis after liver transplantation from a living related donor with Crohn's disease. Gut. 2004 Sep; 53(9):1389-90. View abstract
  89. A pilot study of adalimumab in infliximab-allergic patients. Inflamm Bowel Dis. 2004 Jul; 10(4):333-8. View abstract
  90. The spectrum of gastrointestinal toxicity and effect on disease activity of selective cyclooxygenase-2 inhibitors in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2004 Jul; 10(4):352-6. View abstract
  91. TL1A synergizes with IL-12 and IL-18 to enhance IFN-gamma production in human T cells and NK cells. J Immunol. 2004 Jun 01; 172(11):7002-7. View abstract
  92. High incidence of anergy in inflammatory bowel disease patients limits the usefulness of PPD screening before infliximab therapy. Clin Gastroenterol Hepatol. 2004 Apr; 2(4):309-13. View abstract
  93. Association of antibody responses to microbial antigens and complications of small bowel Crohn's disease. Gastroenterology. 2004 Feb; 126(2):414-24. View abstract
  94. Initial experience with wireless capsule enteroscopy in the diagnosis and management of inflammatory bowel disease. Clin Gastroenterol Hepatol. 2004 Jan; 2(1):31-40. View abstract
  95. Chemokines in inflammatory bowel disease. Curr Allergy Asthma Rep. 2004 Jan; 4(1):83-9. View abstract
  96. Infliximab in the treatment of medically refractory indeterminate colitis. Aliment Pharmacol Ther. 2003 Oct 01; 18(7):741-7. View abstract
  97. CC chemokine receptor 9 expression defines a subset of peripheral blood lymphocytes with mucosal T cell phenotype and Th1 or T-regulatory 1 cytokine profile. J Immunol. 2003 Jul 01; 171(1):159-65. View abstract
  98. Optimizing the therapeutic potential of azathioprine/6-mercaptopurine in the treatment of inflammatory bowel disease. J Clin Gastroenterol. 2003 May-Jun; 36(5):379-81. View abstract
  99. Anti-CD2O chimeric monoclonal antibody (rituximab) treatment of immune-mediated thrombocytopenia associated with Crohn's disease. Gastroenterology. 2003 Feb; 124(2):583. View abstract
  100. Mutations in NOD2 are associated with fibrostenosing disease in patients with Crohn's disease. Gastroenterology. 2002 Sep; 123(3):679-88. View abstract
  101. Diagnosis and misdiagnosis of inflammatory bowel disease. Gastrointest Endosc Clin N Am. 2002 Jul; 12(3):433-49. View abstract
  102. CCR9-positive lymphocytes and thymus-expressed chemokine distinguish small bowel from colonic Crohn's disease. Gastroenterology. 2001 Aug; 121(2):246-54. View abstract
  103. Outcome of cytomegalovirus infections in patients with inflammatory bowel disease. Am J Gastroenterol. 2001 Jul; 96(7):2137-42. View abstract
  104. The role of thymus-expressed chemokine and its receptor CCR9 on lymphocytes in the regional specialization of the mucosal immune system. J Immunol. 2000 Nov 01; 165(9):5069-76. View abstract
  105. The role of chemokines and chemokine receptors in mucosal inflammation. Inflamm Bowel Dis. 2000 Nov; 6(4):303-13. View abstract
  106. Tumor necrosis factor: biology and therapeutic inhibitors. Gastroenterology. 2000 Oct; 119(4):1148-57. View abstract
  107. Role of cytokines in the pathogenesis of inflammatory bowel disease. Annu Rev Med. 2000; 51:289-98. View abstract
  108. Serologic testing in inflammatory bowel disease: its value in indeterminate colitis. Curr Gastroenterol Rep. 1999 Dec; 1(6):482-5. View abstract
  109. An open-label pilot study of low-dose thalidomide in chronically active, steroid-dependent Crohn's disease. Gastroenterology. 1999 Dec; 117(6):1278-87. View abstract
  110. Recurrent bleeding from a duodenal plasmacytoma treated successfully with embolization of the gastroduodenal artery. Am J Gastroenterol. 1999 Jun; 94(6):1691-2. View abstract
  111. Current theories on the causes of inflammatory bowel disease. Gastroenterol Clin North Am. 1999 Jun; 28(2):283-96. View abstract
  112. The role of apoptosis in normal and accelerated lung development in fetal rabbits. J Pediatr Surg. 1999 May; 34(5):863-70; discussion 870-1. View abstract
  113. The changing presentation of pyloric stenosis. Am J Emerg Med. 1999 Jan; 17(1):67-9. View abstract
  114. Predictive value of monitoring parameters in fetal surgery. J Pediatr Surg. 1998 Aug; 33(8):1297-301. View abstract
  115. Temporary tracheal occlusion causes catch-up lung maturation in a fetal model of diaphragmatic hernia. J Pediatr Surg. 1998 Jul; 33(7):1030-7. View abstract
  116. Single-port tracheoscopic surgery in the fetal lamb. J Pediatr Surg. 1998 Jun; 33(6):918-20. View abstract
  117. Stenotrophomonas maltophilia meningitis. Report of two cases and review of the literature. J Neurosurg. 1997 Jul; 87(1):106-8. View abstract
  118. Fetal lung growth after tracheal ligation is not solely a pressure phenomenon. J Pediatr Surg. 1997 Feb; 32(2):347-51. View abstract
  119. Patterns of pulmonary metastasis from uterine cancer. Oncology. 1996 Sep-Oct; 53(5):360-3. View abstract
  120. Natural history of patients with pulmonary metastases from uterine cancer. Cancer. 1996 Aug 01; 78(3):441-7. View abstract
  121. Fluconazole versus amphotericin B in the treatment of hematogenous candidiasis: a matched cohort study. Am J Med. 1996 Aug; 101(2):170-6. View abstract
  122. Bacteremia due to Stenotrophomonas (Xanthomonas) maltophilia: a prospective, multicenter study of 91 episodes. Clin Infect Dis. 1996 Mar; 22(3):508-12. View abstract
  123. Stenotrophomonas (Xanthomonas) maltophilia urinary tract infection. A disease that is usually severe and complicated. Arch Intern Med. 1996 Feb 26; 156(4):433-5. View abstract
  124. Septic prepatellar bursitis caused by Stenotrophomonas (Xanthomonas) maltophilia. Clin Infect Dis. 1996 Feb; 22(2):388-9. View abstract
  125. Stenotrophomonas maltophilia: an unusual cause of biliary sepsis. Clin Infect Dis. 1995 Oct; 21(4):1032-4. View abstract